Study of Amyloid-beta Clearance and Brain Barrier Functions in Alzheimers Disease, Mild Cognitive Impairment, and Subjective Cognitive Decline

What this Trial Is About

Researchers are investigating how the brain clears amyloid-beta protein plaques, focusing on the blood-brain barrier, glymphatic system, brain lymphatic system, and enzymatic breakdown. The study includes participants with Subjective Cognitive Decline, Mild Cognitive Impairment, and mild Alzheimers disease to better understand these clearance mechanisms and their relationship to disease progression. The study uses advanced imaging methods such as 18-Flutemetamol positron emission tomography PET scans, MRI, and cerebrospinal fluid analysis to examine amyloid-beta deposits and blood-brain barrier function. Participants will also wear actigraphy devices to monitor sleep and activity patterns. The study involves a single assessment period without follow-up, aiming to develop a comprehensive model of amyloid-beta clearance and its interaction with brain systems. Participants will undergo detailed clinical and neuropsychological evaluations following a standardized protocol. Researchers will measure differences in blood-brain barrier disruption, clearance mechanisms, brain network connectivity, and the role of sleep in amyloid-beta pathology. The study will last for one visit per participant, including imaging, laboratory tests, and activity monitoring, with no follow-up planned in this phase.

Amyloid-β Clearance Mechanisms in Alzheimer's Disease